FDA official logo
GSRS logo
PFDA official logo

ETESEVIMAB

  • UNII: N7Q9NLF11I
  • Preferred Substance Name: ETESEVIMAB

  • 2423948-94-9
  • ANTI-SARS-COV-2 ANTIBODY JS016
  • CB6
  • CB-6
  • ETESEVIMAB [INN]
  • ETESEVIMAB [USAN]
  • ETESEVIMAB [WHO-DD]
  • IMMUNOGLOBULIN G1 (236-ALANINE,237-ALANINE), ANTI-(SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SPIKE GLYCOPROTEIN RECEPTOR-BINDING DOMAIN) (HUMAN MONOCLONAL JS016 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL JS016 .KAPPA.-CHAIN, DIMER
  • IMMUNOGLOBULIN G1 (236-ALANINE,237-ALANINE), ANTI-(SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SPIKE GLYCOPROTEIN) (HUMAN MONOCLONAL LY3832479 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL LY3832479 .KAPPA.-CHAIN, DIMER
  • JS016
  • JS-016
  • LY COV016
  • LY3832479
  • LY-3832479
  • LY-COV016
  • NP005
  • NP-005

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.




About, Contact Us, Copyright, Privacy, Accessibility

U.S. Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993-0002

U.S. Food and Drug Administration, Health & Human Services

Freedom of Information Act

Powered by

DNAnexus official logo